MARKET

ANAB

ANAB

AnaptysBio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.05
-0.05
-0.18%
Opening 11:50 09/23 EDT
OPEN
28.10
PREV CLOSE
28.10
HIGH
28.21
LOW
27.83
VOLUME
19.59K
TURNOVER
--
52 WEEK HIGH
35.85
52 WEEK LOW
13.92
MARKET CAP
769.51M
P/E (TTM)
-87.8209
1D
5D
1M
3M
1Y
5Y
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-...
GlobeNewswire · 09/09 20:05
Roche announces FDA approval of companion diagnostic for dMMR solid tumors
Roche (OTCQX:RHHBY +0.2%) said that the FDA approved VENTANA MMR RxDx Panel, a companion diagnostic to help identify patients with solid tumors that are deficient in DNA mismatch repair (MMR)
Seekingalpha · 08/18 16:04
Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication
Zacks.com · 08/18 15:04
Sector Update: Health Care Stocks Underperforming Market Wednesday
MT Newswires · 08/18 13:53
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication
Benzinga · 08/18 10:59
Wedbush Lifts AnaptysBio's Price Target to $25 From $20 on Dostarlimab Update; Neutral Rating Kept
MT Newswires · 08/18 06:12
Update: AnaptysBio Gets FDA's Accelerated Approval for Second Indication of GlaxoSmithKline's Jemperli -- Shares Jump Pre-Bell
MT Newswires · 08/18 05:57
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANAB. Analyze the recent business situations of AnaptysBio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANAB stock price target is 35.33 with a high estimate of 50.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 202
Institutional Holdings: 43.10M
% Owned: 157.12%
Shares Outstanding: 27.43M
TypeInstitutionsShares
Increased
25
932.54K
New
15
809.89K
Decreased
50
2.80M
Sold Out
16
317.17K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
+1.19%
Key Executives
Non-Executive Chairman/Independent Director
James Topper
President/Chief Executive Officer/Director
Hamza Suria
Chief Financial Officer
Dennis Mulroy
Chief Operating Officer/General Counsel
Eric Loumeau
Other
Paul Lizzul
Lead Director/Independent Director
Hollings Renton
Independent Director
Dennis Fenton
Independent Director
Laura Hamill
Independent Director
Magda Marquet
Independent Director
Oleg Nodelman
Independent Director
John Schmid
Independent Director
J. Anthony Ware
No Data
  • All
  • Financials
  • Insiders
More
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

Webull offers kinds of AnaptysBio Inc stock information, including NASDAQ:ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.